DIABETIC NEPHROPATHY

1 Metcalfe W AM MacLeod Bennett D on behalf of the Scottish Renal Registry. Equity of renal replacement therapy utilisation: a prospective population based study. QJM 1999; 92:637-42.

2USRDS 1998 Report. Am J Kid Dis 1998; 32(1):38-49.

3 Thomson CRV. Recent advances: nephrology. BMJ 2000; 320:98-101.

4 Phillips AO. Diabetic nephropathy – where next? QJM 2000; 93:643-6.

5 Hasslacher C E Ritz Wahl P Similar risks of nephropathy in patients with type I and type II diabetes mellitus. Nephrol Dial Transplant 1989; 4:859-63.

6 Cowie CC FK Port Wolfe RA Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321:1074-9.

7 Nelson RG WC Knowler Pettitt DJ Diabetic kidney disease in Pima Indians. Diabetes Care 1993; 16(1):335-41.

8 Burden AC PG McNally Feehally J Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med 1992; 9:641-5.

9 Pettitt DJ MF Saad Bennett PH Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1990; 33:438-43.

10 Quinn M MC Angelico Warram JH Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996; 39:940-5.

11 Marre M P Bernadet Gallois Y Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43:384-8.

12 Chowdhury TA MJ Dronsfield Kumar S Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 1996; 39:1108-14.

13 Kunz R JP Bork Fritsche L Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy: A methodological appraisal and systematic review. J Am Soc Nephrol 1998; 9:1653-63.

14 Penno G N Chaturvedi Talmud PJ Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients. Diabetes 1998; 47:1507-11.

15 Parving HH P Jacobsen Tarnow L Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996; 313:591-4.

16Herman WH on behalf of Clinical Evidence. Glycaemic control in diabetes. BMJ 1999; 319:104-6.

17 Kshirsagar AV MS Joy Hogan SL Effect of ACE inhibitors in diabetic and non diabetic chronic renal disease: a systematic overview of randomised placebo controlled trials. Am J Kidney Dis 2000; 35:695-707.

18 El-Nahas AM Tamimi N. The progression of chronic renal failure: a harmful quartet. QJM 1999; 92:421-4.

19 Mogensen CE. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. Journal of the Renin Angiotensin Aldosterone System 2000; 1:234-9.

20The Diabetes Control and Complications Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47:1703-20.

21The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342(6):381-9.

22UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment, and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352:837-53.

23 Hommel E H-H Parving Mathieson E Effect of captopril on kidney function in insulin dependent diabetic patients with nephropathy. BMJ 1986; 293:467-70.

24 Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria (Cochrane Review). In: The Cochrane Library. Issue 4. Oxford: Update Software; 2000.

25 Bjorck S H Mulec Johnsen SA Renal protective effect of Enalapril in diabetic nephropathy. BMJ 1992; 304:339-43.

26 Lewis EJ LG Hunsicker Bain RP for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.

27The EUCLID Study Group. Randomised placebo controlled trial of Lisinopril in normotensive patients with insulin dependent diabetes and normo albuminuria or micro albuminuria. Lancet 1997; 349:1787-92.

28 Ravid M D Brosch Levi Z Use of Enalapril to attenuate decline in renal function in normotensive normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998; 128:982-8.

29Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

30Parving H-H. Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus. Journal of the Renin Angiotensin Aldosterone System 2000; 1:30-1.

31UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-13.

32UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-20.

33GISEN Group. Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non diabetic nephropathy. Lancet 1997; 349:1857-63.

34 Ruggenenti P A Perna Gherardi G Renoprotective properties of ACE inhibition in non diabetic nephropathy with non nephrotic proteinuria. Lancet 1999; 354:359-64.

35Van de Ven PJ, Beutler JJ, Kaatee R Angiotensin converting enzyme inhibitor induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998; 53:986-93.

36 Makanjuola AD M Suresh Laboi P Proteinuria in atherosclerotic renovascular disease. QJM 1999; 92:515-18.

37 Safian RD Textor SC. Medical progress: renal artery stenosis. N Engl J Med 2001; 344:431-42.

38 Bakris GL Weir MR. Angiotensin converting enzyme inhibitor associated elevations in serum creatinine. Arch Intern Med 2000; 160:685-93.

39 Muirhead N BF Feagan , Mahon The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus. A placebo controlled trial. Curr Ther Res 1999; 60:650-60.

40 Coats AJ. Angiotensin receptor blockers – finally the evidence is coming in: IDNT and RENAAL. Int J Cardiol 2001; 79 (2-3):99-102.

41 Ruilope L. RAS blockade: new possibilities in the treatment of complications of diabetes. Heart 2000; 84(1):32-4.

42 Mogensen CE S Neldam Tikkanen I Randomised controlled trial of dual blockade of renin angiotensin system in patients with hypertension, microalbuminuria and non insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000; 321:1440-44.

43 Bakris GL MR Weir De Quattro V Effects of an AE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283-9.

44 Staessen JA WH Birkenhager Fagard RH. Dihydropyridine calcium channel blockers for the treatment of hypertensive diabetic patients. Eur Heart J 2000; 21:2-7.

45Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: the sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNCVI). Arch Intern Med 1997; 154:2413-46.

46 Bakris GL M Williams Dworkin L for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36(3):646-61.

47 Hansson L A Zanchetti Carruthers SG Hypertension Optimal Treatment Study. Lancet 1998; 351:1752-62.

48 Peterson JC S Adler Burkart JM Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-62.

49 Lazarus JM JJ Bourgoignie Buckalew VM for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29:641-50.

50 Stamler J O Vaccero Neaton JD Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-44.

51 Chase HP SK Garg Marshall G Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 1991; 265:614-17.

52 Biesenbach G O Janko Zazgornik J. Similar rate of progression in predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9:1097-102.

53 Krolewski AS JH Warram Christlieb AR. Hypercholesterolaemia – a determinant of renal function loss and deaths in IDDM patients. Kidney Int 1994; 45(Supp):125-31.

54 Sawicki PT U Didjurgeit Muhlhauser I Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17:126-31.

55 Chaturvedi N JM Stephenson Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995; 18:785-92.

56 Tonolo G M Ciccaresse Brizzi P Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long term simvastatin treatment. Diabetes Care 1997; 20:1891-5.

57 Ritz E H Ogata Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 2000; 26(4):54-63.

58 Gin H V Rigalleau Lipids Aparicio M. intake protein and diabetic nephropathy. Diabetes Metab 2000; 26(4):45-53.

59 Manto A P Cotroneo Marra G Effect of intensive treatment on diabetic nephropathy in patients with type 1 diabetes. Kidney Int 1995; 47:231-5.

60 Gaede P P Vedel Parving HH Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617-22.

61 Dunn EJ CJ Burton Feest TG. The care of patients with diabetic nephropathy: audit, feedback and improvement. QJM 1999; 92:443-9.